AMGEN Inc
NASDAQ: AMGN
$337.38
+$1.43 (+0.4%)
Closing Price on September 20, 2024
AMGN Articles
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company...
Published:
Last Updated:
ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers...
Published:
Last Updated:
July 1, 2013: U.S. equity markets opened higher this morning after a blast of economic data from both Asia and Europe. In China, June manufacturing PMI slid lower. Japan’s economics minister said...
Published:
Last Updated:
ThinkstockCancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a buyout offer from Amgen Inc. (NASDAQ:...
Published:
Last Updated:
ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the 28%...
Published:
Last Updated:
U.S. equity markets opened lower this morning on relatively little economic data. In Europe, Germany reported that industrial production rose 1.2%, while a house price index in the U.K.rose 1.1%...
Published:
Last Updated:
ThinkstockThe world of pharmaceuticals may have faced a patent cliff in recent years, but brand name drugs are still generating billions upon billions in annual sales in the United States alone. Some...
Published:
Last Updated:
U.S. equity markets opened lower this morning following a weaker-than-expected employment report from ADP and concern that Friday’s report from the Bureau of Labor Statistics will follow the ADP...
Published:
Last Updated:
Jon OggBiotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many investors, what investors need to know...
Published:
Last Updated:
Investors and traders are always on the lookout for fresh research ideas from Wall Street that will lead to higher income or more profits. 24/7 Wall St. reviews many fresh research calls to find...
Published:
Last Updated:
ThinkstockDrug giant Pfizer Inc. (NYSE: PFE) this morning reported adjusted earnings and revenues that missed analysts estimates, and the stock is down more than 3%. Last week competitor Amgen Inc....
Published:
Last Updated:
Jon OggInvestors love dividends. This one investing component has comprised a major portion of total returns through time. The trend in recent years has been for companies to pay dividends and keep...
Published:
Last Updated:
Jon OggInvestors frequently get to see the analyst upgrades and Buy ratings from Wall St. firms. They often do not get to see or they overlook the analyst downgrades and lists of stocks to sell or to...
Published:
Last Updated:
Jon OggArgus offers what is truly considered to be independent investment research. This gives the firm the lack of any or most of the traditional conflicts of interest that can be the case as far...
Published:
Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to get exposure to....
Published:
Last Updated: